- U.S. Army Rejects Pricing Concerns in Grant of Exclusive Patent License to Sanofi on Zika Vaccine
- KEI, UACT Request that Trump Administration Reevaluate Xtandi Petition
- KEI Statement on House Letter to President Trump on the Protection of Taxpayers’ Rights in Federally-Funded Inventions
- Democrats in House and Senate introduce new drug pricing bill
- KEI statement: 21st meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines
- Dr. Elias Zerhouni defends Sanofi/Army proposed license on Zika patents, and KEI responds
- Maryland House of Delegates passes bill on prescription drug price gouging by vote of 137 to 4
- Leaked document: March 15, 2017 Note by Switzerland on India EFTA TEPA IP Chapter
- Patients, Members of Congress Ask Chilean Government to Issue Compulsory Licenses on Prostate Cancer and HCV Drug Patents
- Leaked: Three documents from RCEP negotiations
This is a link to David Serafino’s blog of the May 30 brownbag discussion on new U.S. trade policy and access to medicine. David’s blog includes comments from a number of persons, including Fabiana Jorge of MFJ International, Rob Weissman of Essential Action, Stephanie Burgos of Oxfam, Brook Baker from Health Gap, Shawn Brown of GPHA, Matt Kavanaugh of Student Global AIDS Campaign, Buddhi Lokuge of Doctors Without Borders, and James Love of Knowledge Ecology International.
Earlier this week, I met in Seoul with civil society fighting the Korus FTA. They are generally opposed to reopening negotiations at this point, but if they do, they hope to have the intellectual property and access to medicines provisions reopened.
According to this GQ story, the H-Prize (HR 632, 110th Congress) passed the House today by a vote of 408 to 8.
Every two years, H-Prizes worth $1 million would be given in four categories: production, storage, distribution and utilization. One $4 million prize would be awarded for hydrogen vehicles. At the end of 10 years, a $10 million grand prize would be given for a “transformational advance in hydrogen energy technology.”
The first American regional meeting on the WHO Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property (IGWG) is scheduled for June 18, 2007 in Washington, DC. This first meeting is organized by PAHO, at the request of the Bolivian Government.
More meetings and working groups are going to be organized this summer and fall in preparation for the II IGWG next November 2007.
To facilitate Latin American governments and civil society effective participation in the WHO IGWG process and their better understanding of some of the proposals, KEI has prepared a report in Spanish.
To access an electronic copy of the report, visit: http://www.keionline.org/index.php?option=com_content&task=view&id=49
Blogging the May 30, 2007 Brownbag Lunch: Discussion on New U.S. Trade Policy and Access to MedicineSubmitted by Staff on 30. May 2007 - 22:00
On May 30, KEI hosted a brown bag lunch discussion on guidelines for the new U.S. trade policy recently released by the Congressional Ways and Means Committee and the Bush Administration. The event began with brief statements by panelists Fabiana Jorge of MFJ International, Rob Weissman of Essential Action, James Love of Knowledge Ecology International, and Stephanie Burgos of Oxfam, followed by a wider discussion.
May 30, 2007, "The New US Trade Agenda and Access to Medicines"
March 16, 2007, Robin Hanson on “Why Grants Won Over Prizes in Science.”
March 15, 2007. Sakiko Fukuda-Parr presents on "The Gene Revolution: GM Crops and Unequal Development."
On 23 May 2007, the 60th World Health Assembly, the World Health Organization’s highest governing body, adopted resolution WHA60.30 on Public health, innovation and intellectual property. This resolution bolstered the work program of WHO’s Intergovernmental Working Group on Public health, innovation and intellectual property (IGWG/PHI). This is the key operative section of the resolution, and the reactions by several key persons.
Venue: 1621 Connecticut Avenue Suite 500, Washington, DC 20009
Knowledge Ecology International will host a brown bag lunch and panel discussion on the generic drug/intellectual property provisions in the guidelines for a new US trade policy recently released by the Congressional Ways and Means Committee and the Bush Administration.
The new trade document is available here:
The final text of the resolution is here:
The Gotham Prize for cancer research tests the use of prizes to encourage more openness for cancer research. According to their web site:
Peter Pitts doesn't like the KSR decision, and he also doesn’t like prizes. His recent Spectator article says:
DISTURBINGLY, SOME FOLKS ARE now advocating a “prize” system where there are no drug patents. Instead, the government would pay a drug maker a lump sum for its innovation, and then the new drug would immediately be placed in the public domain.
KEI statement on bipartisan trade agreement
14 May 2007
FMI: James Love email@example.com, +1.202.361.3040
On May 10, 2007, Speaker Nancy Pelosi and Ways and Means Chair Charles Rangel announced a "new bipartisan " trade package. KEI has reviewed the details of the elements of section III of the agreement, concerning "patents, IPR and access to medicine."